Golgi Phosphoprotein-3 and Y-Box–Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer

Niu, 2008, Diagnosis and treatment for prostate cancer. Chinese–German, J Clin Oncol, 7, 492 Ibrahim, 2014, Cancer incidence in Egypt: results of the national population-based cancer registry program, J Cancer Epidemiol, 21, 1, 10.1155/2014/437971 MacVicar, 2013, Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer, Curr Opin Oncol, 25, 252, 10.1097/CCO.0b013e32835ff161 Klink, 2012, High-grade prostatic intraepithelial neoplasia, Korean J Urol, 53, 297, 10.4111/kju.2012.53.5.297 Epstein, 2006, Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care, J Urol, 175, 820 Poelaert, 2015, The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study, Biomed Res Int, 2015, 10.1155/2015/812815 Wood, 2009, PtdIns4P recognition by Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking, J Cell Biol, 187, 967, 10.1083/jcb.200909063 Scott, 2009, GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer, Nature, 459, 1085, 10.1038/nature08109 Tokuda, 2014, Phosphatidylinositol 4-phosphate in the Golgi apparatus regulates cell–cell adhesion and invasive cell migration in human breast cancer, Cancer Res, 74, 3054, 10.1158/0008-5472.CAN-13-2441 Li, 2012, GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer, J Transl Med, 10, 168, 10.1186/1479-5876-10-168 Hua, 2012, Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer, Diagn Pathol, 7, 127, 10.1186/1746-1596-7-127 Xue, 2014, GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma, Br J Pathol, 110, 2250 Dai, 2015, Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway, J Pathol, 235, 490, 10.1002/path.4479 Hu, 2013, Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer, Tumour Biol, 34, 515, 10.1007/s13277-012-0576-z Zhang, 2015, GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro, Mol Carcinog, 54, 1252, 10.1002/mc.22197 Kohno, 2003, The pleiotropic functions of the Y-box-binding protein, YB-1, Bioessays, 25, 691, 10.1002/bies.10300 Imada, 2013, Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression, Clin Cancer Res, 19, 4638, 10.1158/1078-0432.CCR-12-3705 Kuwano, 2003, The basic and clinical implications of ABC transporters, Y-box binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies, Cancer Sci, 94, 9, 10.1111/j.1349-7006.2003.tb01344.x To, 2010, Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance, Cancer Res, 70, 2840, 10.1158/0008-5472.CAN-09-3155 Gluz, 2009, Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy, J Clin Oncol, 27, 6144, 10.1200/JCO.2008.19.6261 Shiota, 2011, Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression, Endocr Relat Cancer, 18, 505, 10.1530/ERC-11-0017 Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Wedel, 2011, Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the CDK cyclin axis, BMC Cancer, 11, 375, 10.1186/1471-2407-11-375 Moussa, 2009, Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer, BJU Int, 103, 43, 10.1111/j.1464-410X.2008.08059.x Zhou, 2013, GOLPH3 regulates the migration and invasion of glioma cells though RhoA, Biochem Biophys Res Commun, 433, 338, 10.1016/j.bbrc.2013.03.003 Evdokimova, 2009, Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition, Cancer Cell, 15, 402, 10.1016/j.ccr.2009.03.017 Sechi, 2014, GOLPH3 is essential for contractile ring formation and Rab11 localization to the cleavage site during cytokinesis in Drosophila melanogaster, PLoS Genet, 10, e1004305, 10.1371/journal.pgen.1004305 Li, 2015, Increased expression of GOLPH3 is associated with the proliferation of prostate cancer, J Cancer, 6, 420 Scott, 2010, Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis, Clin Cancer Res, 16, 2229, 10.1158/1078-0432.CCR-09-1695 Kunigou, 2011, Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma, Oncol Rep, 26, 1337 Li, 2011, Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study, J Neurooncol, 105, 159, 10.1007/s11060-011-0573-x Romanuik, 2009, Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries, BMC Genomics, 10, 476, 10.1186/1471-2164-10-476 Shiota, 2009, Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth, Cancer Res, 69, 3148, 10.1158/0008-5472.CAN-08-2334 Glockzin, 2006, Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development, J Virol, 80, 3904, 10.1128/JVI.80.8.3904-3911.2006 Law, 2010, Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability, PLoS One, 5, e12661, 10.1371/journal.pone.0012661 Giménez-Bonafé, 2004, YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity, Prostate, 59, 337, 10.1002/pros.20023 Khan, 2014, YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin, Oncotarget, 5, 2462, 10.18632/oncotarget.1790 Habibi, 2008, Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes, Breast Cancer Res, 10, R86, 10.1186/bcr2156 Dahl, 2009, Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer, BMC Cancer, 9, 410, 10.1186/1471-2407-9-410 Panupinthu, 2014, Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer, Oncogene, 33, 2846, 10.1038/onc.2013.259 Rybalkina, 2013, Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance, Vopr Onkol, 59, 623 Finkbeiner, 2009, Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells, Oncogene, 28, 1421, 10.1038/onc.2008.485 Wang, 2014, GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluoracil-based adjuvant chemotherapy, J Transl Med, 12, 15, 10.1186/1479-5876-12-15 Guo, 2013, Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro, Anat Rec (Hoboken), 296, 891, 10.1002/ar.22702